HC Wainwright Reaffirms “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $80.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 202.69% from the stock’s previous close.

CLDX has been the subject of a number of other reports. The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price for the company. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Finally, Citigroup initiated coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Stock Down 4.3 %

Shares of NASDAQ CLDX traded down $1.20 during midday trading on Thursday, hitting $26.43. The stock had a trading volume of 527,893 shares, compared to its average volume of 868,826. Celldex Therapeutics has a 1 year low of $24.43 and a 1 year high of $53.18. The company has a market capitalization of $1.75 billion, a PE ratio of -9.61 and a beta of 1.60. The stock has a 50 day simple moving average of $34.17 and a 200-day simple moving average of $35.97.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The company had revenue of $3.19 million during the quarter, compared to analysts’ expectations of $1.44 million. As a group, analysts expect that Celldex Therapeutics will post -2.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its position in Celldex Therapeutics by 631.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after purchasing an additional 2,664,915 shares in the last quarter. Novo Holdings A S purchased a new position in shares of Celldex Therapeutics during the 2nd quarter worth $31,458,000. Point72 Asset Management L.P. boosted its holdings in Celldex Therapeutics by 51.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after acquiring an additional 654,194 shares during the period. Vanguard Group Inc. boosted its holdings in Celldex Therapeutics by 19.8% during the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after acquiring an additional 604,251 shares during the period. Finally, Marshall Wace LLP boosted its holdings in Celldex Therapeutics by 53.3% during the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after acquiring an additional 479,068 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.